Figure 6.
2D presentation of pyridopyrimidine 5 with EGFR and CDK6 binding site versus Erlotinib and ligand PD0332991, respectively as references. (A) Binding of pyridopyrimidine 5 with EGFR, compared to Erlotinib binding, (B) Binding of pyridopyrimidine 5 with CDK6 versus the ligand PD0332991 binding.